Showing 3731-3740 of 5773 results for "".
- Verana Health Presents Geographic Atrophy and Diabetic Macular Edema Research at ASRS 2022https://modernod.com/news/verana-health-presents-geographic-atrophy-and-diabetic-macular-edema-research-at-asrs-2022/2480976/Verana Health delivered two podium presentations at the American Society of Retina Specialists annual meeting in New York City on July 15. The research findings were generated through analysis of Ophthalmology Qdata, real-world data resulting from the curation
- Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilitieshttps://modernod.com/news/frontera-therapeutics-completes-160-million-series-b-financing-to-fund-clinical-development-and-manufacturing-capabilities/2480975/Frontera Therapeutics announced successful completion of a $160 million Series B funding round. In addition, Frontera announced that the FDA has accepted the company’s investigational new drug (IND) application to initiate a first-in-human clinical trial of FT
- EssilorLuxottica and Politecnico di Milano Launch Partnership to Develop Smart Glasses of the Futurehttps://modernod.com/news/essilorluxottica-and-politecnico-di-milano-launch-partnership-to-develop-smart-glasses-of-the-future/2480974/EssilorLuxottica and Politecnico di Milano have created the first joint research center aimed at designing the smart glasses of the future: EssilorLuxottica Smart Eyewear Lab. The agreement was announced today by Vittorio Colao, Minister for Technological Innovation and Digital Tra
- Bausch + Lomb and Novaliq Submit New Drug Application for Investigational NOV03 for Dry Eye Disease Associated with MGDhttps://modernod.com/news/bausch-lomb-and-novaliq-submission-new-drug-application-for-investigational-nov03-for-dry-eye-disease-associated-with-mgd/2480972/Bausch + Lomb and Novaliq announced the submission of a new drug application (NDA) at the end of June to FDA seeking approval for NOV03 (perfluorohexyloctane), an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease (DED) associated
- Apellis Presents New Phase 3 DERBY and OAKS Data of Intravitreal Pegcetacoplan for GAhttps://modernod.com/news/apellis-presents-new-phase-3-derby-and-oaks-data-of-intravitreal-pegcetacoplan-for-ga/2480970/Apellis Pharmaceuticals announced that five oral presentations and two on-demand papers are being highlighted at the American Society of Retina Specialists Annual Scientific Meeting taking place July 13 -16, 2022 in New York City. New data include
- Genentech: New 2-Year Data Confirm Vabysmo Improves Vision With Fewer Treatments for Wet AMDhttps://modernod.com/news/genentech-new-two-year-data-confirm-vabysmo-improves-vision-with-fewer-treatments-for-people-with-wet-amd/2480965/Genentech announced new 2-year data from the TENAYA and LUCERNE studies that reinforce the long-term efficacy, safety and durability of Vabysmo (faricimab-svoa) in wet age-related macular degeneration (AMD). The 2-year data were presented at the 2022 American Society of Retina Specialis
- Waldo Launches Hydra Boost Plus Lenses in the United Stateshttps://modernod.com/news/waldo-launches-hydra-boost-plus-lenses-in-the-united-states/2480962/Waldo announced the launch of Hydra Boost Plus contact lenses, now available at
- DORC Obtains FDA 510(k) Clearance for Eva Nexus Systemhttps://modernod.com/news/dorc-obtains-fda-510k-clearance-for-eva-nexus-system/2480959/DORC International has announced 510(k) market clearance and the launch of the Eva Nexus. According to DORC, the Eva Nexus features multiple innovations to improve performance, efficiency, and stability for retina surgeons, including Smart IOP for anterior
- Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trialhttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoints-in-dry-eye-disease-chamber-crossover-clinical-trial/2480957/Aldeyra Therapeutics announced the achievement of the primary endpoints in a sequence-randomized, double-masked, vehicle-controlled crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. Reproxalap was st
- Rayner Establishes Direct Presence in Francehttps://modernod.com/news/rayner-establishes-direct-presence-in-france/2480956/Rayner announced its direct entry into the French cataract and refractive market. Based out of Lille in the Hauts-de-France region, Rayner has a growing team of ophthalmic specialist area managers focussed on delivering service and support. Through this team, French ophthalmologist